Gao Wen, Liu Lu, Teng Gao-Jun, Feng Guo-Sheng, Tong Guan-Sheng, Gao Nai-Rong
Nuclear Medicine Technology Institution of Clinical Medical, College of Southeast University, 87 Dinjiaqiao, Nanjing, Jiangsu, 210009, China.
Ann Nucl Med. 2008 Oct;22(8):653-60. doi: 10.1007/s12149-008-0176-6. Epub 2008 Nov 4.
The aim of this work was to study the effectiveness of 32P colloids or microspheres, by arterial interventional administration or stromal injection in the treatment of refractory solid tumors.
By arterial intervention, under the guidance of computerized tomography, X-ray, ultrasonogram, or under direct vision of the surgical field, 32P microspheres (259-685 MBq) or radioactive colloid (281-666 MBq) was administered to 60 cases with refractory solid tumors. Tumor inhibition rate, side effects, survival period, and so on were observed.
The tumor growth was obviously inhibited after the intratumoral injection of 32P colloid. The average survival time in the 60 cases was 35 months with a high tumor inhibition rate (93.4%). Thirty-one cases were completely relieved (51.7%), and 25 cases achieved partial remission (PR, 41.7%). One case with right lobe hepatocellular carcinoma has survived 90 months. The drug was ineffective only in four cases, including one patient who died of gastrointestinal hemorrhage and three of hepatic failure. No other obvious side effects were observed. Intratumoral necrosis, intense fibrosis in the tumor mass, and an integrated capsule encompassing the tumor were revealed by histological examination.
Arterial interventional administration or stromal injection with 32P microspheres or colloid revealed a very fair clinical effectiveness in the treatment of refractory solid tumors. The range of safe effective dosage for 32P glass microspheres and 32P chromic phosphate in one treatment course is 555-740 MBq and 185-370 MBq, respectively.
本研究旨在探讨经动脉介入给药或间质注射32P胶体或微球治疗难治性实体瘤的疗效。
在计算机断层扫描、X射线、超声引导下或直视手术视野下，对60例难治性实体瘤患者经动脉介入给予32P微球（259 - 685MBq）或放射性胶体（281 - 666MBq），观察肿瘤抑制率、副作用、生存期等。
瘤内注射32P胶体后肿瘤生长明显受抑制。60例患者平均生存时间为35个月，肿瘤抑制率高（93.4%）。31例完全缓解（51.7%），25例部分缓解（PR，41.7%）。1例右叶肝细胞癌患者存活90个月。仅4例无效，其中1例死于消化道出血，3例死于肝衰竭。未观察到其他明显副作用。组织学检查显示瘤内坏死、肿瘤块内纤维组织增生明显及肿瘤被完整包膜包裹。
经动脉介入给药或间质注射32P微球或胶体治疗难治性实体瘤临床疗效良好。32P玻璃微球和32P磷酸铬在一个疗程中的安全有效剂量范围分别为555 - 740MBq和185 - 370MBq。
